Abstract:Lung adenocarcinoma (LUAD) is the most frequently observed subtype found in non-small cell lung cancer (NSCLC). Despite its high prevalence, the molecular and histological heterogeneity in LUAD pose a significant challenge for providing effective patient care and aiming to reduce the high mortality rate. The histopathological classification proposed by WHO in 2015 describes five histologic patterns of lung adenocarcinoma (lepidic, acinar, papillary, micropapillary, and solid), and it has been shown that the existence of high-grade subtypes (micropapillary and solid) is associated with poorer survival outcomes. Nevertheless, the specific cellular and molecular mechanisms responsible for these clinical outcome differences based on distinct histological patterns remain unclear. Here, we conducted single-cell RNA sequencing (scRNA-seq) to unveil insights into the tumor microenvironment (TME) and identify cancer cell biomarkers associated with distinct histological patterns. Our study involved 18 specimens from primary LUAD patients who underwent surgical resection, all of whom were previously untreated. These specimens were classified into three groups: acinar/papillary (A/P), micropapillary (MP), and solid. Remarkably, patients with solid-type tumors showed a notable enrichment of CD8+ T cell exhaustion, alongside a significant abundance of GPNMB-high macrophages in the myeloid compartment. Additionally, macrophages from the solid-type demonstrated cholesterol-efflux activation, particularly in alveolar macrophages. It is well-known that cholesterol efflux-activated macrophages display a tumor-associated macrophage phenotype, contributing to immunosuppression in the TME. In contrast, the A/P group exhibited a higher enrichment of mast cells compared to the solid-type. This suggests that the solid-type tumor landscape is more immunosuppressive than the A/P group. In the context of cancer cells, we identified that A/P cancer cells displayed a well-differentiated pattern with a high alveolar epithelial type II cell (AT2) signature. In contrast, solid-type cancer cells showed poorly differentiated states, coupled with a significant activation of the epithelial-mesenchymal transition (EMT) process. Remarkably, even within A/P patients, those with a small portion of solid patterns in the tumor tissue showed higher clonal complexity compared to patients without any solid pattern. Furthermore, we found that cancer cell plasticity can be regulated by cell-cell interactions in the TME. Collectively, this study unveils the relationship between histological patterns and the TME, encompassing distinct immune responses and molecular characteristics of cancer cells in LUAD. These findings provide valuable insights for potential targeted therapeutic strategies. Citation Format: Ju Sung Lee, Ji Yun Jeong, Mi Jeong Hong, Hyo-Gyoung Kang, Jin Eun Choi, Ju Young Kim, Yoon Ha Choi, Jong Kyoung Kim, Shin Yup Lee. Deciphering histological subtype-associated cellular and molecular characteristics of lung adenocarcinoma using single-cell RNA sequencing and spatial transcriptomics [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 2942.

Abstract 3483: SIRT7 as a potential therapeutic target for drug resistance in lung adenocarcinoma: Insights from histone modification-related genes

Abstract 1945: Mechanisms of acquired resistance to EGFR tyrosine kinase inhibitor osimertinib and KRAS-G12C inhibitor sotorasib in lung cancer

Serine hydroxymethyltransferase-2 as regulator of oxidative stress and chemoradiation resistance in lung adenocarcinoma.

Abstract 2151: Identification and proteogenomic characterization of novel lung adenocarcinoma subtypes with therapeutic relevance

Abstract 6496: Assessment of tyrosine kinase inhibitor bypass mechanisms in lung cancer using single cell multiomics, patient derived organoids and rationally designed drug screens

SIRT7 Promotes Lung Cancer Progression by Destabilizing the Tumor Suppressor ARF

Abstract 3277: PAI-1 mediates resistance to MET-targeted therapy in non-small cell lung cancer

Abstract 415: Metabolic reprogramming driven by IGF2BP3-COX6B2 axis promotes acquired resistance to EGFR-TKIs in non-small lung cancer

Abstract 15: Suppression of Adaptive Responses to Targeted Therapies by Transcriptional Inhibition

Methyltransferase like 7B is a potential therapeutic target for reversing EGFR-TKIs resistance in lung adenocarcinoma

Abstract 4048: Comparative effects of SOS1 inhibitor with IL-6 blockade and their combination on Kras mutant lung cancer

Abstract 3867: Chromatin modification driving sub-clonal resistance to KRAS G12C combination therapies in KRAS mutant non-small cell lung cancer

Abstract 3927: Genome-wide screening and validation of molecular targets and biomarkers for lung cancer

Abstract B109: The role of SIRT6 in drug resistance and cellular senescence in cancer.

Abstract 2232: The identification of novel autophagy flux-related molecules closely linked to the acquired resistance to EGFR TKIs in NSCLC patients harboring EGFR mutations

Data from A Meta-analysis of Lung Cancer Gene Expression Identifies <i>PTK7</i> as a Survival Gene in Lung Adenocarcinoma

Abstract 3685: Targeting a novel cell surface serine protease TMPRSS11B for lung cancer therapy

Abstract 5868: Upregulation of HER3 and MET in non-small cell lung cancer cells resistant to EGFR tyrosine kinase inhibitor

Role and potential therapeutic value of histone methyltransferases in drug resistance mechanisms in lung cancer

Abstract PO3-24-05: Cysteine metabolism related ferroptosis sensitivity in trastuzumab resistant HER2 positive breast cancer

Abstract 2942: Deciphering histological subtype-associated cellular and molecular characteristics of lung adenocarcinoma using single-cell RNA sequencing and spatial transcriptomics